Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses.
暂无分享,去创建一个
[1] G. Dougan,et al. Modulation of dendritic cell endocytosis and antigen processing pathways by Escherichia coli heat-labile enterotoxin and mutant derivatives. , 2003, Vaccine.
[2] S. Muller,et al. Immunity under the skin: potential application for topical delivery of vaccines. , 2003, Vaccine.
[3] George K. Lewis,et al. Cholera Toxin and Heat-Labile Enterotoxin Activate Human Monocyte-Derived Dendritic Cells and Dominantly Inhibit Cytokine Production through a Cyclic AMP-Dependent Pathway , 2002, Infection and Immunity.
[4] A. Sharpe,et al. Role of B7 Costimulatory Molecules in the Adjuvant Activity of the Heat-Labile Enterotoxin of Escherichia coli1 , 2002, The Journal of Immunology.
[5] R. Rappuoli,et al. The LTR72 Mutant of Heat-Labile Enterotoxin of Escherichia coli Enhances the Ability of Peptide Antigens To Elicit CD4+ T Cells and Secrete Gamma Interferon after Coapplication onto Bare Skin , 2002, Infection and Immunity.
[6] R. Mumper,et al. Topical immunization using nanoengineered genetic vaccines. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[7] M. Wolf,et al. Safety and Immunogenicity of a Prototype Enterotoxigenic Escherichia coli Vaccine Administered Transcutaneously , 2002, Infection and Immunity.
[8] S. Muller,et al. Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG‐containing oligodeoxynucleotide and effective priming of influenza virus‐specific CD4+ T cells , 2002, Immunology.
[9] C. Elmets,et al. Protection against Tetanus by Needle-Free Inoculation of Adenovirus-Vectored Nasal and Epicutaneous Vaccines , 2001, Journal of Virology.
[10] G. Dougan,et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. , 2001, Vaccine.
[11] S. Muller,et al. Immunization onto bare skin with heat‐labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge , 2001, Immunology.
[12] J. Donnelly,et al. Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant. , 2001, The Journal of infectious diseases.
[13] G. Glenn,et al. Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy. , 2001, Critical reviews in therapeutic drug carrier systems.
[14] S. Akira,et al. A Toll-like receptor recognizes bacterial DNA , 2000, Nature.
[15] H. Uchi,et al. Cytokines and chemokines in the epidermis. , 2000, Journal of dermatological science.
[16] C. Alving,et al. Transcutaneous immunization: A human vaccine delivery strategy using a patch , 2000, Nature Medicine.
[17] P. Iversen,et al. Transdermal delivery of antisense compounds. , 2000, Advanced drug delivery reviews.
[18] G. Dougan,et al. LTK63 and LTR72, two mucosal adjuvants ready for clinical trials. , 2000, International journal of medical microbiology : IJMM.
[19] C. Alving,et al. Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins, Subunits, and Unrelated Adjuvants , 2000, Infection and Immunity.
[20] A. Krieg,et al. The role of CpG motifs in innate immunity. , 2000, Current opinion in immunology.
[21] B. Ryffel,et al. Migration of Langerhans cells and dermal dendritic cells in skin organ cultures: augmentation by TNF‐α and IL‐1 β , 1999, Journal of leukocyte biology.
[22] P. Amerio,et al. Role of cytokines in epidermal Langerhans cell migration , 1999, Journal of leukocyte biology.
[23] F C Kafatos,et al. Phylogenetic perspectives in innate immunity. , 1999, Science.
[24] G. Matyas,et al. Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins as Antigens and Adjuvants , 1999, Infection and Immunity.
[25] L. Simonsen,et al. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. , 1999, Bulletin of the World Health Organization.
[26] G. Matyas,et al. Skin immunization made possible by cholera toxin , 1998, Nature.
[27] K. Heeg,et al. Immunostimulatory DNA: Sequence‐dependent production of potentially harmful or useful cytokines , 1997, European journal of immunology.
[28] C. Harding,et al. CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity , 1997, The Journal of experimental medicine.
[29] D. Sesardic,et al. Interaction of Haemophilus influenzae type b conjugate vaccines with diphtheria-tetanus-pertussis vaccine in control tests. , 1994, Vaccine.
[30] D. Sesardic,et al. The First International Standard for Antitetanus Immunoglobulin, Human; pharmaceutical evaluation and international collaborative study. , 1993, Biologicals : journal of the International Association of Biological Standardization.
[31] B. Spangler,et al. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. , 1992, Microbiological reviews.
[32] G. R. Pullen,et al. Antibody avidity determination by ELISA using thiocyanate elution. , 1986, Journal of immunological methods.